Subscribe to Newsletter


Founded in 2003, Alimera Sciences researches and develops innovative vision-improving treatments for chronic retinal diseases, such as diabetic macular edema (DME), dry age-related macular degeneration (AMD), and retinal vein occlusion.

With a commitment to honesty, integrity, responsibility, candour and trust, Alimera Sciences intend to provide educationally focused content to healthcare professionals across a wide range of topics in DME in order to both increase disease awareness and understanding, and to help improve patient outcomes.

Alimera Sciences Limited

Royal Pavilion, Wellesley Road,
Aldershot, Hampshire,
GU11 1PZ, United Kingdom

Email: [email protected]

Content by Alimera:


Subspecialties Retina

A New Step Forward

| Sponsored by Alimera

Addressing the challenge of diabetic macular edema with ILUVIEN®: views from the Expert User Group Meeting in Rome, November 17, 2018

Subspecialties Retina

Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: A Case Report

| Sponsored by Alimera

Diabetic maculopathy is the most common cause of visual impairment in individuals with diabetes.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine



The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: